Resumen de Investigación

Analyzed using Evidence Intelligence™

Curcumin improves glucose levels in type 2 diabetes patients.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 9 de septiembre de 2026

Key finding

Fasting blood glucose decreased from 130.71 mg/dl to 115.49 mg/dl.

A 12-month study found that curcumin significantly lowered glucose levels in type 2 diabetes patients compared to placebo.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

A 12-month study found that curcumin significantly lowered glucose levels in type 2 diabetes patients compared to placebo.

Clinical relevance

These findings suggest that curcumin could be a beneficial addition to diabetes management strategies, potentially improving glycemic control and reducing the risk of diabetes-related complications. As diabetes prevalence rises, effective and accessible treatments like curcumin could enhance patient outcomes and quality of life.

Keep in mind

The study's sample size may limit the generalizability of the findings. Effects were only observed over a 12-month period; long-term effects remain unclear. The study did not assess potential side effects of curcumin.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Metha Y, Laddawan J, Siwanon J, Somlak C. A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Nutrition Journal. 2024;23:119. doi:10.1186/s12937-024-01022-3

View DOI View on PubMed View on PMC

Efectos Principales

Fasting plasma glucose decreased from 130.71 mg/dl to 115.49 mg/dl (p=0.05).

HbA1c decreased from 6.47% to 6.12% (p=0.05).

HOMA-IR decreased from 6.04 to 4.86 (p=0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Nanocurcumin and Adiponectin, BMI, Beta-cell function, and 4 more.

This study contributes evidence to

Intervention

Nanocurcumin

Outcome

Adiponectin

Evidence topic

Beta-Cell Function

Primary intervention

Nanocurcumin

Primary outcomes

Adiponectin
BMI
Beta-cell function

Evidence topics

Beta-Cell Function Fasting Blood Glucose Glycemic Control HbA1c Reduction

Primary intervention

Nanocurcumin

Primary outcomes

Adiponectin BMI Beta-cell function

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

Why it is useful

Contributes to 7 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

Beta-Cell Function

matched_outcome

Evidencia relacionada

Tema de evidencia

Fasting Blood Glucose

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Adiponectin

Nanocurcumin → Adiponectin

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Beta-cell function

Nanocurcumin → Beta-cell function

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

BMI

Nanocurcumin → BMI

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Nanocurcumin → Fasting Plasma Glucose (FPG)

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Insulin resistance

Nanocurcumin → Insulin resistance

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Mean leptin level change

Nanocurcumin → Mean leptin level change

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Reduction in Hemoglobin A1C levels

Nanocurcumin → Reduction in Hemoglobin A1C levels

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Fasting plasma glucose decreased by 15.22 mg/dl in the curcumin group.
HbA1c levels dropped by 0.35% with curcumin treatment.
HOMA-IR showed a significant decrease of 1.18 units.

A quién se aplica

Adults diagnosed with type 2 diabetes.
Individuals seeking alternative or complementary treatments for diabetes management.

Tener en Cuenta

Results may not apply to populations outside the study sample.
Further research is needed to confirm long-term effects and safety of curcumin.
The study did not include a diverse demographic, which may affect applicability.

Entre Líneas

The study's sample size may limit the generalizability of the findings.
Effects were only observed over a 12-month period; long-term effects remain unclear.
The study did not assess potential side effects of curcumin.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on Nanocurcumin and Adipokine and Angiogenic Markers, Nanocurcumin and Beta-cell Function.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Supplements

Detailed evidence

Nanocurcumin → Adipokine and Angiogenic Markers

Supplements

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

View evidence

Supplements

Detailed evidence

Nanocurcumin → Beta-cell Function

Supplements

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

Adipokine and Angiogenic Markers Evidence Hub

All studies measuring Adipokine and Angiogenic Markers

1 studies

outcome_hub

Measures Adipokine and Angiogenic Markers as a key outcome.

Beta-cell Function Evidence Hub

All studies measuring Beta-cell Function

1 studies

outcome_hub

Measures Beta-cell Function as a key outcome.

Nanocurcumin Evidence Hub

All studies on Nanocurcumin

1 studies

intervention_hub

Contributes to Nanocurcumin evidence base.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Nanocurcumin and Adiponectin

Intervention: NanocurcuminOutcome: Adiponectin

1 results

All studies on Nanocurcumin and Beta-cell function

Intervention: NanocurcuminOutcome: Beta-cell function

1 results

All studies on Nanocurcumin

Intervention: Nanocurcumin

1 results

All studies measuring Adiponectin

Outcome: Adiponectin

1 results

All studies measuring Beta-cell function

Outcome: Beta-cell function

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Nanocurcumin improve adiponectin?

Emerging Evidence

Nanocurcumin appears to improve adiponectin.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Adiponectin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Nanocurcumin affect BMI?

Emerging Evidence

Nanocurcumin appears to affect BMI.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Nanocurcumin improve beta-cell function?

Emerging Evidence

Nanocurcumin appears to improve beta-cell function.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Beta-cell function
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Does Nanocurcumin improve fasting plasma glucose (FPG)?

Emerging Evidence

Nanocurcumin appears to improve fasting plasma glucose (FPG).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Beta-Cell Function Evidence Hub Fasting Blood Glucose Evidence Hub Glycemic Control Evidence Hub HbA1c Reduction Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Nanocurcumin and Adiponectin All studies on Nanocurcumin and BMI All studies on Nanocurcumin and Beta-cell function All studies on Nanocurcumin and Fasting Plasma Glucose (FPG)

Related research

Read related research summaries.

Nanocurcumin shows little effect on diabetic neuropathy symptoms Bariatric surgery improves glucose homeostasis in type 2 diabetes.Combination therapy improves liver health in type 2 diabetes Gluten-free diet improves metabolic health in obese diabetics Enavogliflozin reduces leptin in type 2 diabetes

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.